Full Breakdown
Novo Nordisk Secures UK Approval for Oral Wegovy Pill, Reshaping Obesity Treatment
6/27/2026, 12:26:58 PM
Regulatory Milestone: First Daily Oral GLP-1 Approved in the United Kingdom
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) granted approval for an oral formulation of Wegovy, marking the first daily GLP-1 tablet authorized for weight-management in the UK. The indication covers obese and overweight adults and is to be prescribed with a reduced-calorie diet and exercise. In parallel, the National Institute for Health and Care Excellence (NICE) endorsed the injectable version of Wegovy for cardiovascular-risk reduction, expanding the eligible patient pool.
Clinical Evidence Supporting the Tablet
The OASIS 4 trial reported average weight loss in the low-to-high teen-percentage range for patients adhering to the oral pill, versus low single-digit losses for placebo recipients. Gastro-intestinal side effects and discontinuation rates were noted as key tolerability considerations. Novo Nordisk’s pipeline also includes CagriSema, which achieved a 22.7 % mean weight loss after 68 weeks in the REDEFINE-1 study, and Amycretin, which produced a 14.6 % reduction after 36 weeks in a Phase 2 trial.
Market Context and Investor Reaction
Following the approval, Novo Nordisk’s share price rose roughly 8 % to €42.12, moving above the 200-day moving average of €40.93. The relative strength index reached 71.1, indicating overbought conditions and suggesting a short-term consolidation. The oral tablet is attracting a largely untapped cohort—about 80 % of new users have not previously received GLP-1 therapy—and already accounts for roughly 60 % of all new Wegovy prescriptions in the United States. Analysts view the UK clearance as a template for other European regulators.
Financial Outlook and Operational Considerations
Analysts project a modest decline in earnings over the next three years, emphasizing the need for disciplined execution of the oral launch. Novo Nordisk operates a new production facility in Bohumil, Czech Republic, aimed at alleviating prior supply constraints for Wegovy. The company currently holds about 55 % of the global weekly injectable GLP-1 market, with Wegovy available in more than 55 countries.
Criticism and Structural Headwinds
In the United States, a recent agreement caps monthly GLP-1 therapy costs at $245, pressuring margins. Novo Nordisk plans to reduce list prices for Wegovy and Ozempic in January 2027. Patent expirations on semaglutide are expected in key markets, and generic competition is projected in China, which contributes roughly 6.5 % of group revenue. Eli Lilly’s rival product Foundayo, launched in April 2026, has already secured preference from a major U.S. pharmacy-benefit manager. Management forecasts a 4-12 % decline in currency-adjusted revenue and operating profit for 2026, with pre-tax profit expected to fall 5-13 % due to the U.S. pricing environment.
Future Catalysts and Outlook
The next critical checkpoint is Novo Nordisk’s second-quarter 2026 earnings, where adherence to the oral Wegovy tablet—especially at higher doses—will be closely monitored. An FDA decision on CagriSema is slated for the fourth quarter of 2026; a favorable ruling could bolster the company’s pricing power. With the oral formulation now launched in Europe and production capacity expanding, Novo Nordisk faces a narrow window to grow volume fast enough to offset shrinking per-patient revenue.
